Skinvisible (SKVI) EBITDA Margin Growth (5y) (2015 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) EBITDA Margin Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.06 Bn | 626.30 Bn | 17.26 Bn |
| 2 | AbbVie | 440.06 Bn | 433.49 Bn | 12.70 Bn |
| 3 | Merck | 364.19 Bn | 357.05 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.45 Bn | 260.76 Bn | 11.24 Bn |
| 5 | Pfizer | 158.40 Bn | 146.70 Bn | 10.94 Bn |
| 6 | Sanofi | 52.57 Bn | 45.19 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.32 Bn | 44.32 Bn | - |
| 8 | Incyte | 24.98 Bn | 20.44 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.15 Bn | 18.49 Bn | 683.80 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -231,190.00 |
| Mar 31, 2026 | -159,662.00 |
| Dec 31, 2025 | -230,795.00 |
| Sep 30, 2025 | 238,406.00 |
| Jun 30, 2025 | -271,324.00 |
| Mar 31, 2025 | -198,722.00 |
| Dec 31, 2024 | -288,592.00 |
| Sep 30, 2024 | -128,712.00 |
| Jun 30, 2024 | -175,851.00 |
| Mar 31, 2024 | -71,834.00 |
| Dec 31, 2023 | -152,846.00 |
| Sep 30, 2023 | -152,015.00 |
| Jun 30, 2023 | -166,719.00 |
| Mar 31, 2023 | -144,177.00 |
| Dec 31, 2022 | -240,214.00 |
| Sep 30, 2022 | -113,461.00 |
| Jun 30, 2022 | 79,325.00 |
| Mar 31, 2022 | 109,937.00 |
| Dec 31, 2021 | 65,541.00 |
| Sep 30, 2021 | 119,237.00 |